## Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

ALDER BIO Form 4 July 10, 201	OPHARMACEU	FICALS I	NC								
FORM							OMB A	PPROVAL			
-	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF									
Check th if no lon											
subject to Section 16. Form 4 or	16. <b>SIAIEN</b>	AENT OI	F CHAN	WNERSHIP OF	Estimated burden hou response	urs per					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Litton Mark James			2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
	ALDER BIOPHARMA INC [ALDR]				ARMAC	EUTICAI	ILS (Check all applicable)				
(Last)	(First) (I	Middle)	3. Date of Earliest Transaction				Director 10% Owner X_ Officer (give title Other (specify				
11804 NOF South	(Month/Day/Year) 07/08/2014				below) Chief Business Officer						
	4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check						
BOTHELL	Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting						
(City)	(State)	(Zip)			~ • •	~ •••	Person				
							Acquired, Disposed of		-		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	(D) Price	(Instr. 3 and 4)				
Reminder: Rej	port on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
					inforn requi	nation con red to resp ays a curre	spond to the collectained in this form ond unless the for ntly valid OMB co	are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible	Beneficially Owned securities)	I			
		· D				5 NT 1					

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

8 E

## Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code Securities /Year) (Instr. 8) Acquired (A) or Disposed o (D) (Instr. 3, 4, and 5)		(A) ed of	(Month/Day	(Year)	(Instr. 3 and 4)		(
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (Right to Buy)	\$ 16.9	07/08/2014		A	25,000		<u>(1)</u>	07/07/2014	Common Stock	25,000	
Reporting Owners											
<b>Reporting Owner Name / Address</b>				Rela							
		Director	· 10% O	wner Off	ïcer		Other				
Litton Mark James 11804 NORTH CREEK PARKWAY SOUTH BOTHELL, WA 98011			OUTH	Chief Business Officer							
Signa	turae										

## Signatures

Reporting Person

/s/ Mark James 07/10/2014 Litton \*\*Signature of Date

## **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The shares subject to this option shall vest and become exercisable at a rate of 25% of the total number of shares on the one-year anniversary of the vesting commencement date and 1/48th of the total number of shares each monthly anniversary of the vesting

(1) commencement date thereafter, for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the vesting commencement date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

C